Friday, 4th September 2015
- HSE approves funding for Fampyra, a drug used to treat Multiple Sclerosis.
This is fantastic news and I very much welcome this decision by the HSE, which will benefit many people diagnosed with Multiple Sclerosis. Fampyra has a very positive impact on many people and the decision to fund the drug will change the lives of those people.
Over the last year or more I have met with people with MS and their families. It has been obvious that Fampyra has had a positive impact for many people and it has had a transformative effect on their lives. When trials of the drug ended last year they were very concerned, but now the decision by the HSE to award funding will be reassuring for them.
Fampyra has had a huge impact on the lives of patients with a certain strain of MS. It helps with mobility and walking speed, and also has an impact on hand function, allowing those with the disease to carry out routine functions much more easily. Both the HSE and the manufacturer, Biogen, have been in negotiations for some time, and this positive outcome will benefit many people.